Yahoo Finance Top Stock Reports for Oracle, Abbott & Sanofi
Thursday, August 31, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 15 major stocks, including Oracle Corporation (ORCL), Abbott Laboratories (ABT) and Sanofi (SNY). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Oracle shares have outperformed the Zacks Tech (+47.5% vs. +40.2%) as well as the broader market (+47.5% vs. +18.6% for the S&P 500 index) over the year-to-date period. The company is benefiting from the ongoing momentum across its cloud business, driven by the strong uptake of Oracle Cloud Infrastructure services and Autonomous Database offerings.
Solid adoption of cloud-based applications, comprising NetSuite Enterprise Resource Planning (ERP) and Fusion ERP bodes well. Oracle’s Gen 2 Cloud is delivering better performance at a lower cost due to high bandwidth and low-latency RDMA networks. Partnerships with NVIDIA and Microsoft benefits Oracle.
Oracle is partnering with NVIDIA to build the world's largest high-performance computer, an AI computer, with 16,000 GPUs. The company also announced that it is launching a generative AI cloud service for enterprise customers. However, stiff competition is hurting growth.
(You can read the full research report on Oracle here >>>)
Shares of Abbott have outperformed the Zacks Medical - Products industry over the past six months (+4.6% vs. +0.5%). The company is strategically expanding its global presence to address the unmet demand for advanced medical technologies. Within the EPD business, which is solely based in emerging markets, the Zacks analyst expects Abbott to register a sales CAGR of nearly 5% through fiscal 2025.
Within Core Diagnostics, Abbott is gaining market share following the end of the public health emergency, particularly in the United States and Europe region. Within Diabetes Care, Abbott is scaling up the production of Libre and gaining reimbursement approval in several countries. Innovations and market expansion efforts are helping it offset the impact of inflation and supply disruptions.
However, a steep year-over-year decline in COVID testing-related sales hurt growth. Further, the decision to exit the pediatric nutrition business in China might impede overall growth in the coming period.
(You can read the full research report on Abbott >>)
Sanofi shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+14.8% vs. +9.5%). The company’s specialty Care unit is on a strong footing, particularly with outstanding growth trajectory of Dupixent, which has become the key top-line driver for Sanofi.
Dupixent enjoys strong demand trends across all approved indications and geographies. Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver. Its R&D pipeline is strong. Several data readouts are expected in 2023.
The company has also launched several new drugs in the past couple of years and is expanding its pipeline through M&A deals. However, headwinds include the weak performance of diabetes drugs and recent negative pipeline developments.
(You can read the full research report on Sanofi here >>>)
Other noteworthy reports we are featuring today include Exelon Corporation (EXC), Realty Income Corporation (O) and Hilton Worldwide Holdings Inc. (HLT).
Director of Research
Sheraz Mian
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Oracle (ORCL) Gains from Cloud Suite Adoption & Partnerships
Organic Sales Gain, EPD Business Growth Aid Abbott (ABT)
Dupixent to Remain Sanofi's (SNY) Key Top-Line Driver
Featured Reports
Business Separation & Regulated Investment Aid Exelon (EXC)
Per the Zacks analyst, Exelon's separation from Constellation Energy will allow former to focus on transmission & distribution operations. Its planned $31.3B investment will strengthen operation.
Realty Income (O) to Ride on Solid Tenant Base, Investments
Per the Zacks Analyst, Realty Income is poised to benefit from its focus on service, non-discretionary and low-price retail tenants and accretive investments. However, high interest rates are a woe.
Healthy Backlog, New Orders Aid Dover (DOV) Amid Cost Woes
Per the Zacks analyst, healthy backlogs and new order levels will aid Dover's performance in the upcoming quarters. However, elevated costs and supply chain issues will remain headwinds.
Strong Portfolio & Acquisitions to Drive PTC's Performance
Per the Zacks analyst, PTC's performance is being driven by robust demand for its CAD and PLM products. Weak global macroeconomic conditions along with stiff competition remain concerns.
HydroChemPSC Buyout Aids Clean Harbors (CLH) Amid Liquidity Woes
Per the Zacks analyst, the acquisition of HydroChemPSC has generated multiple cross-selling opportunities for Clean Harbors, Low liquidity remains a concern.
Strong Group Protection Aid Lincoln National (LNC) Amid Cost Woes
Per the Zacks analyst, a resurging group protection business, courtesy of better underwriting, should aid Lincoln National's results. However, higher costs might hamper margins.
New Upgrades
Strong Leisure Demand & Expansion Efforts Aid Hilton (HLT)
Per the Zacks analyst, Hilton is benefiting from solid RevPAR growth owing to strong leisure demand and recovery in international inbound travel. Also, focus on expansion efforts bodes well.
Paylocity Holding (PCTY) Benefits From Growing Customer Base
Per the Zacks Analyst, Paylocity Holding is benefiting from a rising product attach rate and comprehensive product offerings that are helping in expanding its clientele
Backlog Growth & Strategic Initiatives Aid Gibraltar (ROCK)
Per the Zacks analyst, Gibraltar is benefiting from solid backlog levels along with organic growth, improving solar module supply, increased volume and supply-chain optimization initiatives.
New Downgrades
Imperial Oil (IMO) Hurt by High Breakeven Costs
The Zacks analyst is concerned about Imperial Oil's insufficient takeaway capacity and high breakeven costs associated with Canada's oil sands, potentially impacting its profitability
Stiff Competition, Forex Volatility Impairs Catalent (CTLT)
The Zacks analyst is worried about Catalent's operation in a highly competitive market. Unfavorable currency movement is an added issue.
Paramount Global (PARA) Hurt By Dull Media Advertising Revenues
Per the Zacks analyst, sluggish media advertising revenues and declining domestic affiliate revenues are major headwinds for Paramount Global.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY) : Free Stock Analysis Report
Exelon Corporation (EXC) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Oracle Corporation (ORCL) : Free Stock Analysis Report
Realty Income Corporation (O) : Free Stock Analysis Report
Hilton Worldwide Holdings Inc. (HLT) : Free Stock Analysis Report
